BusinessHealthLocal

Wegovy: Novo Nordisk Reduces Heart Attack, Stroke Risk in Non-Diabetic Individuals, Study Reveals

By Harrington Maury Share with new partner:   Share
1,404

New data from an extensive international clinical trial show that Novo Nordisk’s well-known weight-loss medication Wegovy significantly reduced the risk of having a stroke, having a heart attack, or dying from cardiovascular disease in people without diabetes. 

Patients taking semaglutide, the active ingredient in Wegovy as well as Ozempic, for more than three years lost an average of 9.4% of their body weight, compared to the placebo group’s average of 0.9%. 

Based on new information provided at the American Heart Association’s scientific conference over the weekend in Philadelphia. They also had a 20% lower risk of a major cardiovascular event. 

Fifty percent of the patients received either a placebo or Wegovy weekly during the course of the participants’ average three-year follow-up.

Ozempic along with Wegovy demand is driving up the illegal sales of diet pills.

569 (6.5%) of the patients who received the medication experienced a heart attack, stroke, or died from a heart-related cause, as opposed to 701 (8%), or those who received the dummy shot.

Wegovy Participants Loss Weight

Wegovy-Novo-Nordisk-Reduces-Heart-Attack-And-Stroke-Risk-By-20%-Non-Diabetic-Individuals-Study-Reveals
New data from an extensive international clinical trial show that Novo Nordisk’s well-known weight-loss medication Wegovy significantly reduced the risk of having a stroke, having a heart attack, or dying from cardiovascular disease in people without diabetes.

Throughout the course of the study, the Wegovy participants maintained their weight loss gains, losing an average of 10% of their starting weight.

Heart specialist Dr. Martha Gulati of Cedars-Sinai Medical Center in Los Angeles observed that the Wegovy individuals also experienced improvements in their blood pressure, blood sugar, cholesterol, and inflammation.

Novo Nordisk has asked that the FDA list heart benefits on the label for Wegovy, just as they do for Ozempic.

Wegovy is a high-dosage form of Ozempic that has been demonstrated to lower the risk of life-threatening cardiac problems in individuals with diabetes. The fact that this new study focuses on individuals without diabetes is revolutionary.

Participants in the most recent study reported serious adverse reactions, which have been a problem for these types of obesity medications since the beginning.

Due to “adverse events” like nausea, vomiting, and diarrhea, nearly 17% of Wegovy users stopped taking the medication, whereas 8% of the placebo group stopped as well.

Harrington Maury

I'm Harrington Maury, and I've been plunging into the fascinating field of news writing in the dynamic digital website sector for the past 5 years. I've had the pleasure of writing captivating posts that enlighten and engage people from all over the internet while armed with a keyboard and a passion for storytelling.

My expertise has helped me to navigate the ever-changing environment of web journalism, from breaking news to in-depth stories. I've polished my talents in writing short, compelling essays that not only offer information but also engage readers on a deeper level. I've accepted the challenge of keeping up with the fast-paced nature of the digital world, whether it's reporting on the newest trends, covering current events, or investigating thought-provoking issues.

I want to create an immersive experience for readers, creating vivid pictures with words and leaving them with a greater comprehension of the stories at hand, rather than merely delivering facts. With a sharp eye for detail and a dedication to accuracy, I've built a reputation for generating dependable and high-quality material that is appealing to audiences.

As a journalist, I am aware of the power of words and the responsibility that comes with them. I believe in the value of objective reporting while also appreciating the opportunities for creativity and innovation that internet platforms provide. My objective with each piece is to make a lasting impression, ignite conversations, and inspire readers to see the world in new ways.

So, whether it's deconstructing the newest headlines, throwing light on untold stories, or unearthing hidden treasures, I'm here to deliver the news you need in an interesting and thought-provoking manner. Let's go on this journalistic adventure together!

Disclaimer (varies based on content, section, category, etc.): News articles on this site may contain opinions of the author, and if opinion, may not necessarily reflect the views of the site itself nor the views of the owners of The Published Reporter. For more information on our editorial policies please view our editorial policies and guidelines section in addition to our fact checking policy and most importantly, our terms of service. All links on this site could lead to commissions paid to the publisher. Please see Advertising Disclosure in sidebar.
Subscribe to Harrington Maury (via RSS) RSS ICON or a specific category with our Feedburner Feeds. Feedburner
Comment via Facebook

Corrections: If you are aware of an inaccuracy or would like to report a correction, we would like to know about it. Please consider sending an email to [email protected] and cite any sources if available. Thank you. (Policy)

You might also like More from author

Comments are closed.